Cure 360 Webinar Series: Developing an Epigenetic Therapeutic for MECP2 Reactivation

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

Donate

Join Us

cure_360_webinar_youtube_thumbnail_-_mecp2_reactivation_1500_x_700_px

MECP2 reactivation is a cornerstone therapeutic strategy at RSRT. The fact that this strategy is relevant to any and all MECP2 mutations and the fact it should not result in overexpression issues makes it an attractive approach. Expanding knowledge around the mechanics of X chromosome inactivation coupled with advances in scientific technologies that allow for targeting the MECP2 gene makes this an opportune time to double down on our efforts. Thanks to the generosity of our donors RSRT has made a $1.1 million award to Drs. Antonio Bedalov and Kyle Fink.

Learn what has already been accomplished and what is in the works to make this strategy a clinical reality. We welcome your questions.